382 related articles for article (PubMed ID: 26795291)
41. Development of
Kimura H; Matsuda H; Ogawa Y; Fujimoto H; Toyoda K; Fujita N; Arimitsu K; Hamamatsu K; Yagi Y; Ono M; Inagaki N; Saji H
Bioorg Med Chem; 2017 Feb; 25(4):1406-1412. PubMed ID: 28089587
[TBL] [Abstract][Full Text] [Related]
42. Innovative imaging of insulinoma: the end of sampling? A review.
Christ E; Antwi K; Fani M; Wild D
Endocr Relat Cancer; 2020 Apr; 27(4):R79-R92. PubMed ID: 31951592
[TBL] [Abstract][Full Text] [Related]
43. 68Ga-DOTA-Exendin PET-MRI Fusion Imaging in a Case of Insulinoma.
Sood A; Basher RK; Kang M; Shukla J; Behera A; Walia R; Nada R; Mittal BR; Bhattacharya A
Clin Nucl Med; 2019 Jul; 44(7):e428-e430. PubMed ID: 31107750
[TBL] [Abstract][Full Text] [Related]
44. Somatostatin receptor based PET/CT imaging with 68Ga-DOTA-Nal3-octreotide for localization of clinically and biochemically suspected insulinoma.
Sharma P; Arora S; Karunanithi S; Khadgawat R; Durgapal P; Sharma R; Kandasamy D; Bal C; Kumar R
Q J Nucl Med Mol Imaging; 2016 Mar; 60(1):69-76. PubMed ID: 24740163
[TBL] [Abstract][Full Text] [Related]
45. In vivo imaging of the glucagonlike peptide 1 receptor in the pancreas with 68Ga-labeled DO3A-exendin-4.
Selvaraju RK; Velikyan I; Johansson L; Wu Z; Todorov I; Shively J; Kandeel F; Korsgren O; Eriksson O
J Nucl Med; 2013 Aug; 54(8):1458-63. PubMed ID: 23761918
[TBL] [Abstract][Full Text] [Related]
46. Molecular Imaging to the Surgeons Rescue: Gallium-68 DOTA-Exendin-4 Positron Emission Tomography-Computed Tomography in Pre-operative Localization of Insulinomas.
Pallavi UN; Malasani V; Sen I; Thakral P; Dureja S; Pant V; Gaikwad VS; Sabharwal A
Indian J Nucl Med; 2019; 34(1):14-18. PubMed ID: 30713372
[TBL] [Abstract][Full Text] [Related]
47. Utility of
Kalff V; Iravani A; Akhurst T; Pattison DA; Eu P; Hofman MS; Hicks RJ
Intern Med J; 2021 Oct; 51(10):1657-1664. PubMed ID: 33314504
[TBL] [Abstract][Full Text] [Related]
48. Glucagon-like peptide-1 receptor expression after myocardial infarction: Imaging study using
Ståhle M; Kytö V; Kiugel M; Liljenbäck H; Metsälä O; Käkelä M; Li XG; Oikonen V; Saukko P; Nuutila P; Knuuti J; Roivainen A; Saraste A
J Nucl Cardiol; 2020 Dec; 27(6):2386-2397. PubMed ID: 30547299
[TBL] [Abstract][Full Text] [Related]
49. [Lys40(Ahx-DTPA-111In)NH2]-Exendin-4 is a highly efficient radiotherapeutic for glucagon-like peptide-1 receptor-targeted therapy for insulinoma.
Wicki A; Wild D; Storch D; Seemayer C; Gotthardt M; Behe M; Kneifel S; Mihatsch MJ; Reubi JC; Mäcke HR; Christofori G
Clin Cancer Res; 2007 Jun; 13(12):3696-705. PubMed ID: 17575235
[TBL] [Abstract][Full Text] [Related]
50. 68Ga-Exendin-4 PET/CT in Evaluation of Endoscopic Ultrasound-Guided Ethanol Ablation of an Insulinoma.
Luo Y; Li J; Yang A; Yang H; Li F
Clin Nucl Med; 2017 Apr; 42(4):310-311. PubMed ID: 28134698
[TBL] [Abstract][Full Text] [Related]
51. (64)Cu labeled sarcophagine exendin-4 for microPET imaging of glucagon like peptide-1 receptor expression.
Wu Z; Liu S; Nair I; Omori K; Scott S; Todorov I; Shively JE; Conti PS; Li Z; Kandeel F
Theranostics; 2014; 4(8):770-7. PubMed ID: 24955138
[TBL] [Abstract][Full Text] [Related]
52. Ectopic insulinoma diagnosed by 68Ga-Exendin-4 PET/CT: A case report and review of literature.
Zhang X; Jia H; Li F; Fang C; Zhen J; He Q; Liu M
Medicine (Baltimore); 2021 Apr; 100(13):e25076. PubMed ID: 33787590
[TBL] [Abstract][Full Text] [Related]
53. Distinctive detection of insulinoma using [
Murakami T; Fujimoto H; Hamamatsu K; Yamauchi Y; Kodama Y; Fujita N; Fujikura J; Shimizu Y; Nakamoto Y; Kimura H; Saji H; Inagaki N
Sci Rep; 2021 Jul; 11(1):15014. PubMed ID: 34294854
[TBL] [Abstract][Full Text] [Related]
54. Early
Leroy-Freschini B; Amodru V; Addeo P; Sebag F; Vix M; Brunaud L; Klein M; Bahougne T; Bachellier P; Castinetti F; Goichot B; Chevalier E; Taieb D; Imperiale A
Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):686-695. PubMed ID: 30617961
[TBL] [Abstract][Full Text] [Related]
55. Use of the incretin hormone glucagon-like peptide-1 (GLP-1) for the detection of insulinomas: initial experimental results.
Gotthardt M; Fischer M; Naeher I; Holz JB; Jungclas H; Fritsch HW; Béhé M; Göke B; Joseph K; Behr TM
Eur J Nucl Med Mol Imaging; 2002 May; 29(5):597-606. PubMed ID: 11976797
[TBL] [Abstract][Full Text] [Related]
56. Development and Validation of an Analytical HPLC Method to Assess Chemical and Radiochemical Purity of [
Migliari S; Sammartano A; Boss M; Gotthardt M; Scarlattei M; Baldari G; Silva C; Bonadonna RC; Ruffini L
Molecules; 2022 Jan; 27(2):. PubMed ID: 35056858
[No Abstract] [Full Text] [Related]
57. Structure-Activity Relationships and Pharmacokinetics of
Iikuni S; Ohara T; Watanabe H; Ono M
Mol Pharm; 2022 Aug; 19(8):2832-2839. PubMed ID: 35757958
[TBL] [Abstract][Full Text] [Related]
58. Imaging of Insulinoma by Targeting Glucagonlike Peptide-1 Receptor.
Luo Y; Chen X
PET Clin; 2021 Apr; 16(2):205-217. PubMed ID: 33589387
[TBL] [Abstract][Full Text] [Related]
59.
Shah R; Sehemby M; Garg R; Purandare N; Hira P; Mahajan A; Lele V; Malhotra G; Verma P; Rojekar A; Dalvi A; Uchino S; Rastogi S; Lila A; Patil V; Shah N; Bandgar T
Clin Endocrinol (Oxf); 2022 Feb; 96(2):190-199. PubMed ID: 34498757
[TBL] [Abstract][Full Text] [Related]
60.
Tuzcu SA; Pekkolay Z; Kılınç F; Tuzcu AK
J Nucl Med Technol; 2017 Sep; 45(3):198-200. PubMed ID: 28798227
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
